Phase 2 Evidence and Impact Analysis
Article 1 — Zhang et al.: Digital Health Interventions After TKA
PMID: 43024366 | Systematic Review & NMA | n=3,067 (36 RCTs)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | NMAs in digital TKA rehab exist; robotic rehabilitation (RR) superiority is new nuance, but field is active |
| Clinical Relevance | 7 | Directly informs post-TKA rehab prescription; RR and MAT show quantified ROM gains vs. standard care |
| Population Reach | 7 | TKA is one of the most common elective surgeries globally; millions affected annually |
| Implementation Speed | 6 | App-based options near-deployable; robotic rehab requires capital investment |
| Evidence Strength | 7 | 36 RCTs, NMA methodology, n=3,067 — solid, though publication bias possible in component trials |
Key quantitative result: Robotic rehabilitation MD +8.96° active flexion ROM (95% CI 5.86–12.05); MAT MD +6.36° (95% CI 2.81–9.91) vs. conventional rehabilitation. External validation: Network meta-analysis synthesizes multiple RCTs; indirect comparisons introduce uncertainty. Main limitation: Abstract-only access; heterogeneity across RCTs in outcome timing, prosthesis type, and rehab protocols likely underreported. Equity: App-based solutions could democratize access; robotic rehabilitation will remain resource-limited, widening care gaps between high- and low-income settings. Evidence Maturity (revised): Exploratory → Validated (NMA of RCTs with actionable effect sizes) Original triage_score: 7
Article 2 — Chen et al.: Alliin and Cancer Risk via MR
PMID: 43024336 | Mendelian Randomization Meta-analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Alliin-cancer MR studies are emerging but not unprecedented; causal framing adds value over prior observational work |
| Clinical Relevance | 4 | Mechanistic/causal insight into a dietary compound; not yet actionable therapeutically |
| Population Reach | 7 | Prostate, breast, colorectal, ovarian, cervical cancers — broad cancer burden |
| Implementation Speed | 3 | Requires clinical trial validation before any dietary recommendation change |
| Evidence Strength | 5 | MR is methodologically stronger than observational studies but relies on GWAS proxy instruments; pleiotropy risk |
Key quantitative result: Causally reduced risks across multiple cancers (meta-analysis ORs not extractable from abstract); mediated via circulating inflammatory proteins. External validation: No independent cohort validation reported. Main limitation: MR assumes no pleiotropy; alliin GWAS instruments may have limited specificity; abstract-only. Equity: Garlic/alliin availability is globally widespread and low-cost — potential broad equity benefit if validated. Evidence Maturity (revised): Exploratory Original triage_score: 7
Article 3 — Hou et al.: Botulinum Toxin for Glabellar Rhytids
PMID: 43024360 | Meta-analysis | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Botox for glabellar lines is established; personalized/long-lasting strategies are incremental |
| Clinical Relevance | 3 | Aesthetic indication; not a disease-modifying or life-altering intervention |
| Population Reach | 4 | Large cosmetic market, but low disease burden |
| Implementation Speed | 7 | Already in widespread clinical use; refinements immediately adoptable |
| Evidence Strength | 5 | Level of Evidence 3 (therapeutic); meta-analytic synthesis helps but abstract-only limits assessment |
Key quantitative result: Not reported in abstract. External validation: Existing practice; meta-analysis aggregates prior evidence. Main limitation: Level of evidence 3; abstract-only; aesthetic outcome metrics are heterogeneous. Equity: Cost-limited; largely high-income population access. Evidence Maturity (revised): Exploratory Original triage_score: 7 (OpenClaw matching error — this paper was incorrectly matched to precision oncology)
Article 4 — Liao et al.: GLP-1RA vs. DPP-4i/SGLT2i in Bronchiectasis & T2DM
PMID: 43025805 | Propensity-matched Cohort | n=1,029–2,255/group
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First substantial comparative effectiveness study of GLP-1RAs specifically in bronchiectasis — a genuinely understudied combination |
| Clinical Relevance | 7 | Bronchiectasis has very limited disease-modifying therapies; GLP-1RA anti-inflammatory effects could be practice-shaping |
| Population Reach | 6 | Bronchiectasis with T2DM is a specific but sizeable comorbidity group; millions globally |
| Implementation Speed | 5 | GLP-1RAs already prescribed for T2DM; label extension for bronchiectasis requires RCT evidence |
| Evidence Strength | 6 | Propensity-matched real-world cohort is well-powered but observational; unmeasured confounding remains |
Key quantitative result: Specific outcomes (exacerbation rates, hospitalization) not extractable from abstract; propensity matching used. External validation: Single-country (Taiwan) administrative data; needs international replication. Main limitation: Observational design; residual confounding by indication; abstract-only. Equity: GLP-1RAs are expensive and access-limited in LMICs; benefits may not reach highest-burden bronchiectasis populations. Evidence Maturity (revised): Exploratory → trending toward Validated pending RCT Original triage_score: 7
Article 5 — Song et al.: Outdoor Activity and Dementia Risk, China
PMID: 43024373 | National Cohort | n=8,758 | Follow-up: 4.33 years
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Physical activity–dementia association well-established; individualized outdoor activity frequency framing adds marginal novelty |
| Clinical Relevance | 6 | Practically actionable non-pharmacological recommendation; 25% HR reduction is clinically meaningful |
| Population Reach | 8 | Dementia affects ~55 million globally; elderly population worldwide |
| Implementation Speed | 8 | Zero-cost behavioral intervention; immediately recommendable pending confirmation |
| Evidence Strength | 5 | Large national cohort; observational with reverse-causation risk (prodromal dementia reduces outdoor activity); medium classification confidence |
Key quantitative result: HR 0.75 (95% CI 0.62–0.92) for daily vs. near-never outdoor activity; 25% relative risk reduction. External validation: China-specific cohort; generalizability to other cultural/geographic contexts unclear. Main limitation: Observational; reverse causation plausible; medium classification confidence; abstract-only. Equity: Low-cost intervention, broadly accessible; however, safety concerns about outdoor activity differ by environment (urban pollution, crime). Evidence Maturity (revised): Exploratory Original triage_score: 7
Article 6 — Shinwari et al.: rTSA vs. aTSA Adverse Events Meta-analysis
PMID: 43022650 | Systematic Review/Meta-analysis | n=1,445,486
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | rTSA safety concerns are known; this provides the largest quantified synthesis to date |
| Clinical Relevance | 7 | Very large effect sizes (OR 1.71 for 30-day readmission); directly informs surgical consent and planning |
| Population Reach | 6 | Shoulder arthroplasty volume is rising rapidly; hundreds of thousands annually |
| Implementation Speed | 7 | Findings directly applicable to pre-operative counseling and risk stratification |
| Evidence Strength | 7 | 46 studies, n>1.4M — exceptional scale despite retrospective component studies |
Key quantitative result: rTSA vs. aTSA — OR 1.38 SAEs (95% CI 1.10–1.74); OR 1.71 30-day readmission (1.47–1.98); OR 1.50 90-day readmission. External validation: Meta-analysis aggregates multiple independent datasets. Main limitation: Retrospective component studies; selection bias (rTSA used in older/frailer patients); abstract-only. Equity: Affects all shoulder arthroplasty patients; rTSA is disproportionately performed in elderly women. Evidence Maturity (revised): Exploratory → Validated (large-scale synthesis) Original triage_score: 7
Article 7 — Molica et al.: CLL Frontline BTK Inhibitor Delphi Consensus
PMID: 43025972 | Systematic Review + Delphi Consensus | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | BTK inhibitor dominance in CLL is established; real-world frailty/CV stratification framework adds practical value |
| Clinical Relevance | 7 | Directly bridges guideline and practice for CLL; addresses TP53 disruption, frailty, cardiovascular scoring |
| Population Reach | 5 | CLL-specific; ~200,000 new cases/year globally |
| Implementation Speed | 7 | Consensus framework is immediately applicable in CLL clinical practice |
| Evidence Strength | 5 | Expert consensus/Delphi — high agreement rates but inherently subjective; systematic review underpins it |
Key quantitative result: 94.6–100% consensus for cBTKi monotherapy in high-risk/frail subgroups. External validation: Based on landmark trial data; consensus doesn't generate new primary evidence. Main limitation: Italian regional expert panel; may not reflect global practice variation; abstract-only. Equity: Framework may improve access to appropriate therapy for underserved elderly/frail CLL patients who are often undertreated. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 8 — Ma et al.: Agent Orange and MGUS-Related Cancers in Veterans
PMID: 43024788 | Retrospective Cohort | n=3,246 veterans
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | First focused study on AO exposure modifying MGUS-to-cancer progression rate |
| Clinical Relevance | 5 | Important null result for a specific veteran population; surveillance implications |
| Population Reach | 4 | Specific to Vietnam-era veterans with MGUS; smaller but underserved population |
| Implementation Speed | 5 | Null finding doesn't change surveillance but informs risk counseling |
| Evidence Strength | 5 | Cohort design; limited by poor exposure data quality (acknowledged by authors); abstract-only |
Key quantitative result: AO exposure did not significantly modify cancer development rates (specific HRs not extractable from abstract). External validation: None; single VA cohort. Main limitation: Poor exposure data quality; small cancer event counts; abstract-only. Equity: Direct relevance to a historically underserved military veteran population. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 9 — Jang et al.: Deep Learning on Peripheral Blood Smear for Systemic Disease
PMID: 43024355 | Development + Internal Validation | n=51,369
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Using PBS morphology beyond cell type counts to predict systemic inflammatory states and comorbidities is genuinely novel |
| Clinical Relevance | 6 | Potential to extract additional diagnostic value from a routine test; AUROCs ~0.85–0.90 for inflammation markers |
| Population Reach | 7 | Peripheral blood smear is performed globally across all clinical settings |
| Implementation Speed | 4 | Requires external validation and regulatory clearance before deployment |
| Evidence Strength | 5 | Large n but internal validation only; medium classification confidence; observational |
Key quantitative result: AUROC 0.891/0.896 for CRP; 0.849/0.822 for septic shock (development/holdout). External validation: Internal holdout only — no external cohort validation. Main limitation: Internal validation only; did not outperform demographic model for CVD/DM — clinical added value uncertain. Equity: If validated, could democratize inflammatory state screening in settings without access to CRP/ESR assays. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 10 — Zhang et al.: CBC ML for Lipemia-Induced Hemoglobin Bias
PMID: 43021805 | Cohort Study | n=283
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Specific laboratory QC application; technically novel but narrow scope |
| Clinical Relevance | 5 | Directly corrects a known measurement error affecting anemia diagnosis |
| Population Reach | 5 | Affects any lipemic patient requiring hemoglobin measurement — not rare |
| Implementation Speed | 6 | Could integrate into laboratory software pipelines relatively quickly |
| Evidence Strength | 4 | Very small n=283; R²=0.848 is promising but needs prospective validation |
Key quantitative result: OOF R²=0.848 for hemoglobin bias prediction; MAE 1.20 percentage points. External validation: None; single cohort. Main limitation: Very small sample; single-site; abstract-only. Equity: Improves lab accuracy for all patients, including those in settings without ultracentrifuge sample preparation. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 11 — Friederike et al.: HER2-Targeted Therapy in Gastroesophageal Cancer
PMID: 43025815 | Review Article | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Trastuzumab deruxtecan (T-DXd) in GEA is established; this review synthesizes the evolving landscape |
| Clinical Relevance | 7 | HER2+ GEA treatment algorithm is actively evolving; review consolidates actionable second-line evidence |
| Population Reach | 6 | Gastroesophageal cancer is globally common (~1.1M cases/year); ~15–20% are HER2+ |
| Implementation Speed | 6 | T-DXd already approved in second-line; review informs immediate clinical application |
| Evidence Strength | 4 | Review/observational; not primary data; medium classification confidence |
Key quantitative result: T-DXd improves second-line outcomes (specific HR/OS data not in abstract). External validation: Synthesizes existing trial data. Main limitation: Review design; abstract-only; medium confidence classification. Equity: T-DXd access highly inequitable globally — high cost limits use to high-income countries. Evidence Maturity (revised): Exploratory (as review) Original triage_score: 6
Article 12 — Janjigian et al.: ctDNA to Direct Adjuvant Immunotherapy in dMMR Tumors
PMID: 43025593 | Phase II Trial | n=184 screened / 13 ctDNA-positive treated
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | ctDNA-guided PD-1 blockade for MRD across tumor-agnostic dMMR cancers post-surgery — highly novel precision approach |
| Clinical Relevance | 8 | 85% ctDNA clearance at 6 months is striking; concept of MRD-directed adjuvant immunotherapy is practice-shaping if confirmed |
| Population Reach | 6 | dMMR tumors span multiple cancer types; ~5% of all solid tumors; broad but not universal |
| Implementation Speed | 4 | Phase II; needs Phase III confirmation; ctDNA infrastructure not universally available |
| Evidence Strength | 6 | Phase II, n=13 MRD-positive treated patients — compelling signal but very small active-treatment cohort |
Key quantitative result: ctDNA clearance 11/13 (85%) at 6 months in MRD-positive patients receiving PD-1 blockade. External validation: None yet; hypothesis-generating Phase II. Main limitation: Only 13 patients received active treatment; no randomized control arm; surrogate endpoint (ctDNA clearance) not yet validated as survival surrogate. Equity: dMMR testing and ctDNA platforms require infrastructure investment; inequitable access in resource-limited settings. Evidence Maturity (revised): Exploratory → Potentially Practice-Changing (if Phase III confirms) Original triage_score: 6
Article 13 — Sagawa et al.: Postop Management After CRLM Resection
PMID: 43024157 | Critical Review of Randomized Evidence | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Adjuvant chemo after CRLM resection is an established but unresolved debate |
| Clinical Relevance | 6 | Synthesis of RCT evidence informs post-surgical management decisions |
| Population Reach | 6 | Colorectal liver metastases affect a substantial proportion of CRC patients (~25–30%) |
| Implementation Speed | 5 | No new therapy; clarifies existing options |
| Evidence Strength | 6 | Review of randomized evidence; design quality moderate |
Key quantitative result: Adjuvant fluoropyrimidine/oxaliplatin delays recurrence in some settings but no durable OS benefit demonstrated. External validation: Synthesizes existing RCTs. Main limitation: Lack of OS benefit despite DFS gains; heterogeneous trial populations; abstract-only. Equity: Standard chemotherapy regimens are widely available; no access disparity introduced. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 14 — Manners et al.: Sleep Apnea Endotype Profiling for Oral Appliance Response
PMID: 43026159 | Observational Cohort | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Scalable endotyping in a large clinical cohort is novel; physiology-based algorithm for OA response prediction adds value |
| Clinical Relevance | 6 | Matching OSA patients to oral appliances vs. CPAP could substantially improve adherence and outcomes |
| Population Reach | 7 | OSA affects ~1 billion people globally |
| Implementation Speed | 5 | Algorithm needs prospective validation before clinical adoption |
| Evidence Strength | 5 | Observational; medium confidence; sample size not stated in abstract |
Key quantitative result: AHI mean 28±23 events/h; endotype heterogeneity demonstrated across a large cohort (sample size not specified in abstract). External validation: Not reported. Main limitation: Observational; abstract-only; sample size unclear; medium classification confidence. Equity: Oral appliances are more affordable than CPAP in many settings; better matching could improve access equity. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 15 — Reinshagen et al.: DL-Accelerated Cochlear MRI
PMID: 43025904 | Randomized Study | n=49 (1.5T), 34 (3T)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | DL MRI acceleration is an active field; cochlear/IAC-specific application is incremental |
| Clinical Relevance | 5 | Improves throughput for inner ear imaging; meaningful for audiological practice |
| Population Reach | 4 | Cochlear/IAC imaging is a subset of neuroradiology |
| Implementation Speed | 6 | DL reconstruction tools are becoming commercially available |
| Evidence Strength | 6 | Randomized comparison; small n but controlled design |
Key quantitative result: SDL+ARDL significantly superior to ARDL alone across all five image quality domains at both field strengths (FDR-adjusted p<0.001). External validation: None; single-center. Main limitation: Small n; single-center; abstract-only. Equity: Faster MRI could increase access in high-volume, resource-strained settings. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 16 — Zadorozhna et al.: ASO Therapy for Cryptic Splicing in IRDs
PMID: 43022838 | Translational/Patient-Derived Models | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Systematic workflow from genome sequencing → cryptic variant ID → ASO rescue across SDCCAG8, CEP290, ABCA4 is methodologically novel |
| Clinical Relevance | 4 | Pre-clinical (patient-derived cells); no human trial data yet — cannot exceed 5 |
| Population Reach | 5 | Rare inherited retinal dystrophies, Bardet-Biedl syndrome; small population but very high unmet need |
| Implementation Speed | 3 | ASO therapy requires IND filing, trials; 5–10 year timeline |
| Evidence Strength | 5 | Strong mechanistic data in patient-derived models; not clinical; medium confidence |
Key quantitative result: At least one ASO successfully improved normal splicing and increased gene expression for each of three cryptic variants. External validation: Validated across three distinct genes/diseases — internal cross-validation. Main limitation: Pre-clinical; patient-derived cell models may not predict in vivo efficacy; abstract-only. Equity: Rare disease populations historically underserved by therapy development; this workflow could accelerate personalized ASO access. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 17 — Bożek et al.: Dupilumab + HDM SLIT in Atopic Dermatitis (3-Year RCT)
PMID: 43025695 | RCT | n=15 | 3-year follow-up
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | 3-year combination data for dupilumab + SLIT in AD is novel; most trials are ≤12 months |
| Clinical Relevance | 6 | Sustained benefit concept is important for chronic AD management |
| Population Reach | 6 | Atopic dermatitis affects ~10% of adults globally |
| Implementation Speed | 5 | Both agents already approved; combination use off-label — needs larger trial |
| Evidence Strength | 4 | n=15 is very small for an RCT; severely underpowered for subgroup conclusions |
Key quantitative result: All groups improved at 12 months; sustained at 3 years (quantitative data not in abstract). External validation: None; needs larger confirmatory RCT. Main limitation: n=15 — critically underpowered; abstract-only. Equity: Dupilumab is expensive; combination therapy further increases cost burden. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 18 — Franco et al.: Therapeutic Pipeline for Rare ILDs
PMID: 43025460 | Review (Phase III context) | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Review of pipeline; olipudase alfa for ASMD is established; synthesizes known advances |
| Clinical Relevance | 6 | Rare ILD populations have very high unmet need; enzyme replacement and gene therapy advances meaningful |
| Population Reach | 4 | Ultra-rare ILDs; small absolute population but severe disease |
| Implementation Speed | 5 | Some agents already approved (olipudase alfa); others in pipeline |
| Evidence Strength | 5 | Review citing Phase III data; not primary |
Key quantitative result: Significant progress across three rare ILD disease areas noted (specific metrics not in abstract). External validation: Synthesizes existing trial evidence. Main limitation: Review design; abstract-only; heterogeneous diseases grouped together. Equity: Orphan drug access is highly inequitable; benefits concentrated in wealthy countries. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 19 — LIFT-HCC Investigators: Pre-LT ICI Use and Post-Transplant Outcomes in HCC
PMID: 43025725 | Prospective Multicenter Global Study | n=408
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Largest prospective global dataset on ICI-to-liver-transplant outcomes; identifies rejection risk factors systematically |
| Clinical Relevance | 8 | Directly addresses a critical and controversial clinical decision point; non-HBV etiology and irAEs as rejection predictors are actionable |
| Population Reach | 6 | HCC is the 6th most common cancer; liver transplant-eligible subset is smaller but high-stakes |
| Implementation Speed | 6 | Findings immediately applicable to transplant waitlist management and ICI washout protocols |
| Evidence Strength | 6 | Prospective multicenter design is strongest observational evidence available for this question; n=408 is meaningful |
Key quantitative result: HCV etiology aSHR=3.86; non-viral aSHR=2.55; irAEs aSHR=1.87 (95% CI 1.11–3.14) for post-LT rejection; >90-day ICI washout protective. External validation: Multicenter, multinational (global LIFT-HCC consortium) — partial external validation built in. Main limitation: Observational; selection bias (who received ICI vs. not); abstract-only; unmeasured confounders. Equity: Liver transplantation itself is highly inequitable by geography and socioeconomic status. Evidence Maturity (revised): Exploratory → Potentially Practice-Changing in ICI-to-transplant protocols Original triage_score: 6
Article 20 — Acharya: SGLT2 Inhibitors for Peripartum Cardiomyopathy (Commentary)
PMID: 43022501 | Commentary/Call for Trial
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Relevance | 5 | SGLT2 inhibitors in PPCM is an underexplored hypothesis with plausible biological rationale |
| Clinical Relevance | 7 | PPCM has 20% mortality in high-risk groups and no specific approved therapy; SGLT2i hypothesis is urgent |
| Population Reach | 5 | PPCM is relatively rare (~1:2,000 deliveries) but disproportionately affects young women |
| Implementation Speed | 2 | No trial exists yet; call for one — 5–10 year pathway at minimum |
| Evidence Strength | 3 | Commentary with no primary data |
Key quantitative result: Up to 50% incomplete LV recovery and 20% mortality in high-risk PPCM populations on standard therapy. External validation: N/A — no trial. Main limitation: No primary data; hypothesis only. Equity: PPCM disproportionately affects Black women in the US — high equity stakes for a targeted trial. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 21 — Doma et al.: Semaglutide vs. Tirzepatide in ASCVD without Diabetes
PMID: 43022342 | Retrospective Propensity-Matched Study | n=5,665/group
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Head-to-head sema vs. tirze in ASCVD without T2DM; direct cardiovascular comparisons are sparse |
| Clinical Relevance | 7 | Clinicians prescribing in ASCVD without T2DM need comparative CV data |
| Population Reach | 8 | Obesity + ASCVD without T2DM is a large and growing population |
| Implementation Speed | 5 | Real-world data; head-to-head RCT needed before guideline change |
| Evidence Strength | 5 | Retrospective; propensity-matched; unmeasured confounding; abstract-only |
Key quantitative result: Specific CV outcome differences between agents not extractable from abstract. External validation: Single real-world database; needs prospective RCT. Main limitation: Retrospective; no randomization; event rates and HR not in abstract. Equity: Both agents have access disparities; findings relevant to insured patients. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 22 — Lin et al.: GLP-1RA Neuroprotection in Neurodegeneration (Review)
PMID: 43025540 | Narrative Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | GLP-1RA neuroprotection is an active, growing field; this review synthesizes mechanisms |
| Clinical Relevance | 5 | Variable real-world signal emerging; not yet actionable |
| Population Reach | 8 | Alzheimer's + Parkinson's affect tens of millions globally |
| Implementation Speed | 4 | Phase III trials underway but not completed |
| Evidence Strength | 4 | Review; preclinical + early clinical; medium confidence |
Key quantitative result: None quantitative in abstract; preclinical mechanistic evidence across multiple pathways described. External validation: N/A — review. Main limitation: Clinical data "variable"; no primary data; medium confidence. Equity: If GLP-1RAs prove neuroprotective, access inequity would be a major concern given current pricing. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 23 — Brazzolotto et al.: Loneliness and Medication Non-adherence in Older Adults
PMID: 43024654 | Cross-sectional Multicenter | n=134
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Loneliness–adherence link is conceptually established; independent association with implementation-phase non-adherence adds specificity |
| Clinical Relevance | 5 | Intervention target identification is useful; loneliness screening in pharmacy/clinic feasible |
| Population Reach | 7 | Medication non-adherence in older adults is ubiquitous globally |
| Implementation Speed | 6 | Loneliness assessment tools exist; could be integrated into pharmacy consultations |
| Evidence Strength | 4 | n=134; cross-sectional; medium confidence; abstract-only |
Key quantitative result: Loneliness, practical and belief barriers independently associated with higher odds of non-adherence (ORs not in abstract). External validation: Multicenter (Brazil) — limited generalizability. Main limitation: Small n; cross-sectional (causal direction uncertain); medium confidence. Equity: Addresses loneliness as a structural barrier — particularly relevant for socially isolated elderly populations. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 24 — Kitano et al.: iPPFE Presenting as Vocal Cord Paralysis (Case Report)
PMID: 43025207 | Case Report | n=1
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | iPPFE-to-vocal cord paralysis pathway is rare and underrecognized |
| Clinical Relevance | 4 | Single case; raises differential diagnosis awareness |
| Population Reach | 2 | Ultra-rare disease (iPPFE) |
| Implementation Speed | 6 | Diagnostic awareness immediately applicable |
| Evidence Strength | 2 | Single case report |
Key quantitative result: None applicable. External validation: N/A — case report. Main limitation: n=1; cannot establish incidence or generalizability. Equity: Rare disease populations consistently underdiagnosed; awareness studies have disproportionate value. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 25 — Laguna et al.: rADAMTS13 Long-Term Real-World Data in Congenital TTP
PMID: 43023126 | Multicenter Retrospective Cohort | n=10
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First long-term real-world safety/efficacy data for rADAMTS13 in cTTP in Poland; meaningful for an ultra-rare disease |
| Clinical Relevance | 7 | For cTTP, every patient-level data point matters; no treatment discontinuation in any patient is a meaningful safety signal |
| Population Reach | 2 | cTTP is ultra-rare (~1/million); judged relative to relevant clinical population with high unmet need |
| Implementation Speed | 7 | rADAMTS13 (Cablivi equivalent) already approved; real-world confirmation supports continued use |
| Evidence Strength | 4 | n=10; retrospective; Cureus journal (open peer review); abstract-only |
Key quantitative result: All 10 patients maintained rADAMTS13 prophylaxis without permanent discontinuation or regimen modification. External validation: None; single-country multi-site. Main limitation: Extremely small n inherent to disease rarity; retrospective; Cureus peer review model. Equity: Ultra-rare disease with almost no treatment options; real-world data is equity-relevant for this population. Evidence Maturity (revised): Exploratory (but clinically meaningful given disease rarity) Original triage_score: 6
Article 26 — Corssac et al.: MSC-Derived EVs in Pulmonary Hypertension Mouse Model
PMID: 43022829 | Animal Model Study | Mouse
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Human BM-MSC-derived EVs in PH mouse model; meaningful mechanistic data |
| Clinical Relevance | 3 | Animal model only — capped at 5 per rules; PH is a rare disease with high unmet need |
| Population Reach | 3 | PH is rare (~15–50/million); pre-clinical |
| Implementation Speed | 2 | Pre-clinical; 10+ year translation timeline |
| Evidence Strength | 5 | Controlled animal study with quantitative outcomes |
Key quantitative result: EV treatment: TAPSE +37.1±2.6% (p=0.0011); RV hypertrophy reduction 18.6±7.6% (p=0.0218) vs. vehicle. External validation: None; single animal model. Main limitation: Murine model; EV manufacturing scalability; no human data. Equity: PH disproportionately affects young women; EV therapy could be transformative if developed. Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 27 — Vivek et al.: Aortic Rupture as Presentation of MZL (Case Report)
PMID: 43022957 | Case Report | n=1
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Rare presentation; clinical awareness value |
| Clinical Relevance | 4 | Multidisciplinary alert for vascular surgeons and hematologists |
| Population Reach | 2 | Extremely rare event |
| Implementation Speed | 5 | Diagnostic awareness immediately applicable |
| Evidence Strength | 2 | Single case report; medium confidence |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 28 — Lv & Liu: IgG Glycosylation as Cancer Liquid Biomarker (Review)
PMID: 43025476 | Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Antigen-specific IgG glycosylation as biomarker is an emerging and somewhat novel framing |
| Clinical Relevance | 4 | Framework not yet validated; speculative biomarker |
| Population Reach | 7 | Potential pan-cancer liquid biopsy application |
| Implementation Speed | 2 | No validated assay; 5–10 years minimum |
| Evidence Strength | 3 | Review proposing a framework; no primary validation data |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 29 — Fan et al.: CRISPR/Cas13a-ML Platform for Lung Cancer miRNA Liquid Biopsy
PMID: 43024743 | Proof-of-Concept Study | n=50 plasma samples
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CRISPR-CHA dual-readout + ML for multiplex miRNA detection is technically innovative |
| Clinical Relevance | 4 | Pre-clinical validation; 50 plasma samples; not yet clinical tool |
| Population Reach | 7 | Lung cancer is the leading cause of cancer death globally |
| Implementation Speed | 3 | Technology requires analytical validation, regulatory pathway |
| Evidence Strength | 4 | 50-sample clinical validation; no independent cohort; medium confidence |
Key quantitative result: Attomolar detection limit; 10-order-of-magnitude dynamic range; high agreement with qRT-PCR in 50 samples. Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 30 — Qiu et al.: Mitochondrial Dysfunction in SLE via Multi-Scale Transcriptomics
PMID: 43023808 | Computational/Observational | Unknown species
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SCO2 as primary core gene in SLE MRC dysfunction — potentially novel target |
| Clinical Relevance | 3 | Mechanistic discovery; diagnostic model accuracy not fully defined in abstract |
| Population Reach | 5 | SLE affects ~5 million globally |
| Implementation Speed | 2 | Requires wet-lab validation and clinical study |
| Evidence Strength | 3 | Transcriptomic/computational; no functional validation in abstract; species unclear |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 31 — Jiang et al.: Tau Spread Links Seizures and Alzheimer's Disease
PMID: 43022618 | Transcriptomic + Mouse Model | Human/Mouse
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Bidirectional seizure-Tau propagation interaction is mechanistically novel and well-supported |
| Clinical Relevance | 5 | Mechanistic insight; not immediately therapeutic but could inform anti-seizure therapy in AD |
| Population Reach | 8 | AD affects 55M globally; seizure comorbidity in AD is common |
| Implementation Speed | 2 | Basic science; 10+ years to therapeutic application |
| Evidence Strength | 5 | Mouse model validated; transcriptomic integration; human data limited |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 32 — Lv et al.: MOF Chemical Nose for Depression Biomarker Detection
PMID: 43025947 | Proof-of-Concept | Unknown species
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | MOF sensor array for neurotransmitter biomarkers is technically novel |
| Clinical Relevance | 3 | 100% classification accuracy in controlled samples — not yet clinical |
| Population Reach | 7 | Depression affects 300M+ globally |
| Implementation Speed | 2 | No clinical validation; laboratory prototype |
| Evidence Strength | 2 | Proof-of-concept with unknown sample source; species unclear |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 33 — Memariani & Memariani: Gut Dysbiosis in MS Review
PMID: 43022363 | Review | Unknown species
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | MS gut microbiome is well-characterized; phageome/archaeome adds marginal novelty |
| Clinical Relevance | 4 | No actionable therapeutic recommendation; broad hypothesis generation |
| Population Reach | 6 | MS affects ~2.8 million globally |
| Implementation Speed | 2 | Microbiota-targeted therapy in MS is speculative |
| Evidence Strength | 3 | Review; species unknown |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 34 — Baugh et al.: CVA21 for Ewing Sarcoma (Preclinical)
PMID: 43022387 | In vitro / Patient-Derived Models | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ICAM-1 as biomarker for CVA21 efficacy in Ewing sarcoma is a novel biomarker-therapy pairing |
| Clinical Relevance | 3 | In vitro only — capped at 5; rare pediatric cancer with unmet need |
| Population Reach | 3 | Ewing sarcoma: ~1 per million; judged relative to affected population |
| Implementation Speed | 2 | Preclinical; first-in-human trials not yet initiated |
| Evidence Strength | 5 | Patient-derived ex vivo models are more clinically representative than cell lines |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 35 — Zhang et al.: CRISPR in Glioblastoma (Review)
PMID: 43023242 | Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CRISPR in GBM is an active field; this review summarizes existing work |
| Clinical Relevance | 4 | No primary clinical data; GBM has terrible prognosis and high unmet need |
| Population Reach | 5 | GBM: ~3/100,000 incidence; devastating disease |
| Implementation Speed | 2 | CRISPR-based GBM therapy is early preclinical |
| Evidence Strength | 3 | Review; medium confidence |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 36 — Yang et al.: Lysine Lactylation and Cancer Resistance (Review)
PMID: 43023236 | Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Lactylation as a metabolic-epigenetic node driving treatment resistance is a relatively new and important concept |
| Clinical Relevance | 4 | Mechanistic review; no therapeutic validated yet |
| Population Reach | 7 | Applies broadly to multiple cancer types |
| Implementation Speed | 2 | No lactylation-targeting agent in trials |
| Evidence Strength | 3 | Review; medium confidence |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 37 — Wang et al.: Engineered Bacteria for Tumor Immunotherapy (Preclinical)
PMID: 43022414 | Mouse Model | Unknown
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | In situ-activated bacteria releasing dual therapeutic proteins is a genuinely creative immunotherapy delivery platform |
| Clinical Relevance | 3 | Mouse model only — capped at 5; impressive pre-clinical results |
| Population Reach | 6 | Potential broad solid tumor application |
| Implementation Speed | 2 | Preclinical; major regulatory hurdles for bacterial therapies |
| Evidence Strength | 4 | Mouse model; 83.7% tumor suppression and 2x survival are strong pre-clinical signals |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 38 — Li et al.: MiWAS for Aging Research (Methods)
PMID: 43024211 | Methods Article | Unknown species
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | MiWAS framework is a useful methodological extension of GWAS to mitochondrial genetics |
| Clinical Relevance | 3 | Methods/tools paper; no clinical data |
| Population Reach | 6 | Aging research; broad population relevance |
| Implementation Speed | 4 | Tool availability accelerates research |
| Evidence Strength | 4 | Methods paper; cohort design claimed but abstract-only |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 39 — Badhesha et al.: Epigenetic Clock Calculation Protocol
PMID: 43024197 | Protocol/Methods | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Epigenetic clocks are well-established; this is a standardized protocol |
| Clinical Relevance | 4 | Research tool; some emerging clinical application in geroscience |
| Population Reach | 6 | Aging research; broad relevance |
| Implementation Speed | 5 | Protocol immediately usable by researchers |
| Evidence Strength | 4 | Protocol article; no primary outcome data |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 40 — Zhang et al.: Inflammaging and Senescence in Postmenopausal Depression
PMID: 43023986 | Prospective Study/Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SASP-depression link in postmenopausal women adds mechanistic framing to a recognized clinical problem |
| Clinical Relevance | 5 | Mechanistic; no therapeutic tested; raises hypothesis for senolytic trials |
| Population Reach | 7 | Postmenopausal depression is common and undertreated globally |
| Implementation Speed | 2 | No therapeutic ready |
| Evidence Strength | 4 | Primarily mechanistic review framing; prospective label unclear from abstract |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 41 — Saxena et al.: AAV Gene Editing for Fabry Disease in Mice
PMID: 43023180 | Mouse Model | Human/Mouse
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Hepatocyte-targeted GLA cDNA insertion via AAV achieving long-term correction across multiple mutation types is highly relevant |
| Clinical Relevance | 3 | Mouse model — capped at 5; Fabry disease has existing ERT |
| Population Reach | 3 | Fabry disease: ~1–9/100,000; rated relative to affected rare population |
| Implementation Speed | 2 | Preclinical; IND and clinical trials 5–10 years away |
| Evidence Strength | 5 | Strong preclinical data in Gla KO mice; both newborn and juvenile intervention studied |
Evidence Maturity (revised): Exploratory Original triage_score: 5
Article 42 — Prather et al.: Lifestyle Medicine Program Pre-Arthroplasty
PMID: 43022359 | Observational | n=292 | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Prehabilitation concept is established; intensive vs. selective track comparison adds modest novelty |
| Clinical Relevance | 6 | Persistent pain 26% vs. 10% post-op is clinically important |
| Population Reach | 6 | Hip/knee arthroplasty is extremely common |
| Implementation Speed | 6 | Lifestyle medicine programs exist; replication feasible |
| Evidence Strength | 4 | Non-randomized; observational; n=292; medium confidence |
Evidence Maturity (revised): Exploratory Original triage_score: 6
Article 43 — Kumar et al.: Arrhythmogenic Cardiomyopathy Review
PMID: 43023990 | Review | Human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Desmosomal genetics of ACM are well characterized; review synthesizes pathogenesis-to-treatment |
| Clinical Relevance | 5 | ACM carries sudden cardiac death risk; review informs management |
| Population Reach | 4 | Rare genetic cardiomyopathy (~1/5,000) |
| Implementation Speed | 4 | Management strategies evolving but limited novel options |
| Evidence Strength | 3 | Review; medium confidence |
Evidence Maturity (revised): Exploratory Original triage_score: 5